Breakthrough daptomycin-, linezolid-, vancomycin-resistant Enterococcus faecium bacteremia during protracted daptomycin therapy: A case report

[1]  D. van Duin,et al.  Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I) , 2021, Open forum infectious diseases.

[2]  M. Gilmore,et al.  Evolution of vancomycin-resistant Enterococcus faecium during colonization and infection in immunocompromised pediatric patients , 2020, Proceedings of the National Academy of Sciences.

[3]  Samuel Kaski,et al.  Plasmids Shaped the Recent Emergence of the Major Nosocomial Pathogen Enterococcus faecium , 2020, mBio.

[4]  Peter T. McKenney,et al.  Diversification and Evolution of Vancomycin-Resistant Enterococcus faecium during Intestinal Domination , 2019, Infection and Immunity.

[5]  S. Abraham,et al.  Antimicrobial-resistant CC17 Enterococcus faecium: The past, the present and the future. , 2019, Journal of global antimicrobial resistance.

[6]  Mónica A. García-Solache,et al.  The Enterococcus: a Model of Adaptability to Its Environment , 2019, Clinical Microbiology Reviews.

[7]  Matthew H. Greene,et al.  Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid–Nonsusceptible Vancomycin-Resistant Enterococcus , 2018, Open forum infectious diseases.

[8]  Yee-Chun Chen,et al.  A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections , 2018, Scientific Reports.

[9]  B. Gu,et al.  The emerging problem of linezolid-resistant enterococci. , 2017, Journal of global antimicrobial resistance.

[10]  M. Rybak,et al.  β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. , 2015, The Journal of antimicrobial chemotherapy.

[11]  P. Cocconcelli,et al.  Enterococcus faecium PBP5-S/R, the Missing Link between PBP5-S and PBP5-R , 2014, Antimicrobial Agents and Chemotherapy.

[12]  V. Nizet,et al.  Ceftaroline Restores Daptomycin Activity against Daptomycin-Nonsusceptible Vancomycin-Resistant Enterococcus faecium , 2013, Antimicrobial Agents and Chemotherapy.

[13]  V. Nizet,et al.  Treatment of High-Level Gentamicin-Resistant Enterococcus faecalis Endocarditis with Daptomycin plus Ceftaroline , 2013, Antimicrobial Agents and Chemotherapy.

[14]  G. Weinstock,et al.  Whole-Genome Analysis of a Daptomycin-Susceptible Enterococcus faecium Strain and Its Daptomycin-Resistant Variant Arising during Therapy , 2012, Antimicrobial Agents and Chemotherapy.

[15]  Cesar A. Arias,et al.  The rise of the Enterococcus: beyond vancomycin resistance , 2012, Nature Reviews Microbiology.

[16]  G. Weinstock,et al.  Genetic basis for in vivo daptomycin resistance in enterococci. , 2011, The New England journal of medicine.

[17]  R. Humphries,et al.  Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  C. Arias,et al.  Management of multidrug-resistant enterococcal infections. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  L. Rice,et al.  Gene Dosage and Linezolid Resistance in Enterococcus faecium and Enterococcus faecalis , 2002, Antimicrobial Agents and Chemotherapy.

[20]  G. Satta,et al.  Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium , 1994, Antimicrobial Agents and Chemotherapy.